The present invention relates to an implantable paste comprising bioactive glass powder having a size distribution of 0.5-45 m, bioactive glass granules having a size distribution between 100 and 4000 m, low molecular weight polyethylene glycol having a molecular weight range of 200-700 g/mol, medium molecular weight polyethylene glycol having a molecular weight range of 700-2500 g/mol, high molecular weight polyethylene glycol having a molecular weight range of 2500-8000 g/mol and glycerol. The composition of the bioactive glass is 45-55 weight-% of SiO.sub.2, 20-25 weight-% of Na.sub.2O, 18-25 weight-% of CaO and 3-6 weight-% of P.sub.2O.sub.5, and the molecular weight of the low molecular weight polyethylene glycol and of the medium molecular weight polyethylene glycol differ from each other by at least 80 g/mol and that the molecular weight of the medium molecular weight polyethylene glycol and of the high molecular weight polyethylene glycol differ from each other by at least 300 g/mol.

A method for controlling generation of biologically desirable voids in a composition placed in proximity to bone or other tissue in a patient by selecting at least one water-soluble inorganic material having a desired particle size and solubility, and mixing the water-soluble inorganic material with at least one poorly-water-soluble or biodegradable matrix material. The matrix material, after it is mixed with the water-soluble inorganic material, is placed into the patient in proximity to tissue so that the water-soluble inorganic material dissolves at a predetermined rate to generate biologically desirable voids in the matrix material into which bone or other tissue can then grow.

Provided herein are settable and non-settable compositions for use in surgical procedures comprising a variety of disclosed particles and optionally including previously unclotted, lyophilized, optionally crosslinked mammalian blood plasma. Also provided are related compositions, including surgical kits and packages, as well as methods of making and using the compositions.

Provided herein are settable and non-settable compositions for use in surgical procedures comprising a variety of disclosed particles and optionally including previously unclotted, lyophilized, optionally crosslinked mammalian blood plasma. Also provided are related compositions, including surgical kits and packages, as well as methods of making and using the compositions.

The present invention relates to an implantable paste comprising bioactive glass powder having a size distribution of 0.5-45 m, bioactive glass granules having a size distribution between 100 and 4000 m, low molecular weight polyethylene glycol having a molecular weight range of 200-700 g/mol, medium molecular weight polyethylene glycol having a molecular weight range of 700-2500 g/mol, high molecular weight polyethylene glycol having a molecular weight range of 2500-8000 g/mol and glycerol. The composition of the bioactive glass is 45-55 weight-% of SiO.sub.2, 20-25 weight-% of Na.sub.2O, 18-25 weight-% of CaO and 3-6 weight-% of P.sub.2O.sub.5, and the molecular weight of the low molecular weight polyethylene glycol and of the medium molecular weight polyethylene glycol differ from each other by at least 80 g/mol and that the molecular weight of the medium molecular weight polyethylene glycol and of the high molecular weight polyethylene glycol differ from each other by at least 300 g/mol.

The present invention relates to an implantable paste comprising bioactive glass powder having a size distribution of 0.5-45 m, bioactive glass granules having a size distribution between 100 and 4000 m, low molecular weight polyethylene glycol having a molecular weight range of 200-700 g/mol, medium molecular weight polyethylene glycol having a molecular weight range of 700-2500 g/mol, high molecular weight polyethylene glycol having a molecular weight range of 2500-8000 g/mol and glycerol. The composition of the bioactive glass is 45-55 weight-% of SiO.sub.2, 20-25 weight-% of Na.sub.2O, 18-25 weight-% of CaO and 3-6 weight-% of P.sub.2O.sub.5, and the molecular weight of the low molecular weight polyethylene glycol and of the medium molecular weight polyethylene glycol differ from each other by at least 80 g/mol and that the molecular weight of the medium molecular weight polyethylene glycol and of the high molecular weight polyethylene glycol differ from each other by at least 300 g/mol.

A medical device includes fibroin and a polyphosphate salt including a polyphosphate and a salt counter ion. The fibroin is derived from Lepidoptera and the medical device is selected from spun or knitted fibers, non-woven, woven, sponge, foam, membrane, film, 3D scaffold, particles, and powders.

Provided herein are bone hemostatic and adhesive compositions for use in surgical procedures comprising a variety of disclosed particles. Also provided are related compositions, including surgical hardware, surgical kits and packages, as well as methods of making and using the compositions.

Provided herein are bone hemostatic and adhesive compositions for use in surgical procedures comprising a variety of disclosed particles. Also provided are related compositions, including surgical hardware, surgical kits and packages, as well as methods of making and using the compositions.

A bone substitute composition includes a bone substitute matrix and a conditioning solution. The bone substitute matrix includes 85% to 98% by weight of alkaline calcium phosphate powder, 1% to 10% by weight of a polymer, and 1% to 5% by weight of a crosslinker. The conditioning solution includes 90% to 97% by weight of water, 1% to 5% by weight of a phosphate, and 1% to 5% by weight of a water-soluble acidic compound.